Recently, a Delaware jury awarded $100 million to a woman who sued a manufacturer of vaginal mesh devices on the basis of negligence, breach of warranty, and fraud.1 This case may represent the tip of the iceberg because many similar litigation cases are pending. Although the lay press has focused on the judicial aspect and the potential financial fallout for manufacturers, little attention has been paid to understanding the factors associated with adverse events after vaginal mesh-based procedures. Indeed, the US Food and Drug Administration has called for intensified efforts to study the risks of implantable mesh in postmarket surveillance studies.2 However, the results of these efforts are still underway.3